LONDON, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announces the completion of enrollment of the pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback